About point capital inc - SILO
Silo Pharma, Inc. is a developmental stage biopharmaceutical company, which engages in the merging of traditional therapeutics with psychedelic research. It seeks to acquire and develop intellectual property or technology rights from universities and researchers to treat rare diseases, including the use of psychedelic drugs. The company was founded by Eric Weisblum on July 13, 2010 and is headquartered in Sarasota, FL.
SILO At a Glance
Silo Pharma, Inc.
677 North Washington Boulevard
Sarasota, Florida 34236
| Phone | 1-718-400-9031 | Revenue | 72.10K | |
| Industry | Pharmaceuticals: Major | Net Income | -3,700,683.00 | |
| Sector | Health Technology | Employees | 3 | |
| Fiscal Year-end | 12 / 2024 | |||
| View SEC Filings |
SILO Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 61.51 |
| Price to Book Ratio | 0.678 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.838 |
| Enterprise Value to Sales | -44.80 |
| Total Debt to Enterprise Value | N/A |
SILO Efficiency
| Revenue/Employee | 24,034.00 |
| Income Per Employee | -1,233,561.00 |
| Receivables Turnover | N/A |
| Total Asset Turnover | 0.007 |
SILO Liquidity
| Current Ratio | 9.904 |
| Quick Ratio | 9.904 |
| Cash Ratio | 9.883 |
SILO Profitability
| Gross Margin | -1,116.975 |
| Operating Margin | -5,347.424 |
| Pretax Margin | -5,036.036 |
| Net Margin | -5,132.566 |
| Return on Assets | -37.455 |
| Return on Equity | -43.966 |
| Return on Total Capital | -58.785 |
| Return on Invested Capital | -43.966 |
SILO Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | N/A |
| Total Debt to Total Assets | N/A |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |